Completed PHASE4 INTERVENTIONAL 1-arm NCT00502853

A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.

Sponsor: Hoffmann-La Roche

Conditions Rheumatoid Arthritis

Interventions Methotrexate rituximab [MabThera/Rituxan]

Updated 9 times since 2017 Last updated: Jul 7, 2017 Started: Oct 25, 2007 Primary completion: Jul 23, 2010 Completion: Jul 23, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00502853, this PHASE4 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Sep 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Sep 2017 [monthly]

Completed PHASE4

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Genoa, Italy